$1.43
+0.00 (+0.00%)
Open$1.41
Previous Close$1.43
Day High$1.51
Day Low$1.41
52W High$11.64
52W Low$1.09
Volume—
Avg Volume670.7K
Market Cap41.21M
P/E Ratio—
EPS$-1.92
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,079.7% upside
Current
$1.43
$1.43
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 57.6K | 112.3K | 11.20M |
| Net Income | -53,462,675 | -93,757,613 | 1.78M |
| Profit Margin | -91,866.0% | -87,272.7% | 15.9% |
| EBITDA | -53,364,700 | -98,785,005 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -48.7% | -48.7% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |